Protective role of Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukaemia and COVID‐19

Thibaud, Santiago; Tremblay, Douglas; Bhalla, Sheena; Zimmerman, Brittney S.; Sigel, Keith; Gabrilove, Janice

doi:10.1111/bjh.16863

Cited by 72 publications

(103 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The authors suggest that BTKi can be protective against COVID-19 induced lung injury due to their role in reduction of proinflammatory cytokines in lung tissues. Another study also found similar beneficial effect in patients who continued BTKi during hospitalization for COVID-19 ( 13 ). Currently two phase two clinical trials are investigating possible beneficial effect of BTKi (acalabrutinib and zanubrutinib) in COVID-19 ( ClinicalTrials.gov Identifier: NCT04346199, NCT04382586).…”

mentioning

confidence: 63%

See 1 more Smart Citation

A Case of COVID-19–Induced Lymphocytosis in a Patient With Treatment-Naive CLL: Should It Be treated?

Safarpour

Srinivasan

Farooqui

et al. 2021

Clinical Lymphoma Myeloma and Leukemia

View full text Add to dashboard Cite

mentioning

confidence: 63%

“…Another study also found similar beneficial effects in patients who had continued BTK inhibitors during hospitalization for COVID-19. 13 Two…”

Section: Covid-19einduced Lymphocytosis and Treatment-naive Cllmentioning

confidence: 99%

A Case of COVID-19–Induced Lymphocytosis in a Patient With Treatment-Naive CLL: Should It Be treated?

Safarpour

Srinivasan

Farooqui

et al. 2021

Clinical Lymphoma Myeloma and Leukemia

View full text Add to dashboard Cite

“… Ambulatory cancer patients with COVID-19 (WHO 1-2) To shorten time to recovery or increase survival Remdesivir D III 98 Hydroxychloroquine (+/- azithromycin) D II u 2 , 99 Lopinavir/ritonavir D III No reference. Dexamethasone D II t 100 Tocilizumab D III 101 Anakinra D II h,t 102 Barcitinib D III No reference. Convalescent plasma D III No reference.…”

Section: Treatmentmentioning

confidence: 99%

“… Convalescent plasma D III No reference. Hospitalized cancer patients with COVID-19, no oxygen therapy (WHO 3) To shorten time to recovery Remdesivir, d1 200mg/d, d2-10 100mg/d A II t 98 Convalescent plasma C II t,u 103 , 104 To increase survival Remdesivir, d1 200mg/d, d2-10 100mg/d C II t 98 Convalescent plasma D II t,u 103 , 104 To shorten time to recovery or increase survival Baricitinib d1-14 4mg/d C II t 105 Hydroxychloroquine (+/- azithromycin) D II u 2 , 99 Lopinavir/ritonavir D II t 106 Dexamethasone D I 100 Tocilizumab D III 101 Anakinra D II h,t 102 Hospitalized cancer patients with COVID-19, oxygen therapy (WHO 4-7) To shorten time to recovery Remdesivir, d1 200mg/d, d2-10 100mg/d A II t 98 Convalescent plasma C II t,u 103 , 104 To increase survival ...…”

Section: Treatmentmentioning

confidence: 99%

Evidence-based management of COVID-19 in cancer patients: Guideline by the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO)

Giesen

Sprute²,

Rüthrich

et al. 2020

European Journal of Cancer

View full text Add to dashboard Cite

Since its first detection in China in late 2019 the novel coronavirus SARS-CoV-2 and the associated infectious disease COVID-19 continue to have a major impact on global health care and clinical practice. Cancer patients, in particular those with haematological malignancies, seem to be at an increased risk for a severe course of infection. Deliberations to avoid or defer potentially immunosuppressive therapies in these patients need to be balanced against the overarching goal of providing optimal antineoplastic treatment. This poses a unique challenge to treating physicians. This guideline provides evidence-based recommendations regarding prevention, diagnostics and treatment of SARS-CoV-2 infection and COVID-19 as well as strategies towards safe antineoplastic care during the COVID-19 pandemic. It was prepared by the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO) by critically reviewing the currently available data on SARS-CoV-2 and COVID-19 in cancer patients applying evidence-based medicine criteria.

show abstract

“…receptor (TLR) and IL-1b signaling). The Bruton's tyrosine kinase inhibitor acalabrutinib, used for chronic lymphocytic leukemia (CLL) and involved in the inhibition of TLR7/8, has shown beneficial effects on CLL/COVID-19 patients(82) and is currently undergoing clinical trials for COVID-19. Drugs against chemokine receptors may reduce CRS in COVID-19 patients by…”

mentioning

confidence: 99%

COVID-19–Induced Modifications in the Tumor Microenvironment: Do They Affect Cancer Reawakening and Metastatic Relapse?

et al. 2020

View full text Add to dashboard Cite

Severe coronavirus disease 2019 (COVID-19) causes an uncontrolled activation of the innate immune response, resulting in acute respiratory distress syndrome and systemic inflammation. The effects of COVID-19-induced inflammation on cancer cells and their microenvironment are yet to be elucidated. Here, we formulate the hypothesis that COVID-19-associated inflammation may generate a microenvironment favorable to tumor cell proliferation and particularly to the reawakening of dormant cancer cells (DCCs). DCCs often survive treatment of primary tumors and populate premetastatic niches in the lungs and other organs, retaining the potential for metastatic outgrowth. DCCs reawakening may be promoted by several events associated to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, including activation of neutrophils and monocytes/macrophages, lymphopenia and an uncontrolled production of pro-inflammatory cytokines. Among pro-inflammatory factors produced during COVID-19, neutrophil extracellular traps (NETs) released by activated neutrophils have been specifically shown to activate premetastatic cancer cells disseminated in the lungs, suggesting they may be involved in DCCs reawakening in COVID-19 patients. If confirmed by further studies, the links between COVID-19, DCCs reactivation and tumor relapse may support the use of specific anti-inflammatory and anti-metastatic therapies in patients with COVID-19 and an active or previous cancer.

show abstract

Protective role of Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukaemia and COVID‐19

Cited by 72 publications

References 14 publications

A Case of COVID-19–Induced Lymphocytosis in a Patient With Treatment-Naive CLL: Should It Be treated?

A Case of COVID-19–Induced Lymphocytosis in a Patient With Treatment-Naive CLL: Should It Be treated?

Evidence-based management of COVID-19 in cancer patients: Guideline by the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO)

COVID-19–Induced Modifications in the Tumor Microenvironment: Do They Affect Cancer Reawakening and Metastatic Relapse?

Contact Info

Product

Resources

About